Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CYTK NASDAQ:KRYS NASDAQ:NUVL NASDAQ:TARS On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$80.01+1.1%$72.05$32.22▼$80.80$9.85B0.421.93 million shs2.08 million shsKRYSKrystal Biotech$340.21-0.9%$299.25$130.50▼$356.50$10.12B0.53300,486 shs272,740 shsNUVLNuvalent$123.44+0.0%$106.91$71.13▼$123.62$9.75B1.155.03 million shs1.34 million shsTARSTarsus Pharmaceuticals$66.17+4.1%$62.87$38.51▼$85.25$2.73B0.49594,378 shs1.29 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+0.50%+10.91%+2.90%+31.91%+144.13%KRYSKrystal Biotech-1.33%+5.75%+14.69%+38.99%+159.27%NUVLNuvalent-0.01%+0.06%+20.86%+28.36%+64.56%TARSTarsus Pharmaceuticals+0.63%+2.76%+2.09%+0.65%+56.36%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCYTKCytokinetics$80.01+1.1%$72.05$32.22▼$80.80$9.85B0.421.93 million shs2.08 million shsKRYSKrystal Biotech$340.21-0.9%$299.25$130.50▼$356.50$10.12B0.53300,486 shs272,740 shsNUVLNuvalent$123.44+0.0%$106.91$71.13▼$123.62$9.75B1.155.03 million shs1.34 million shsTARSTarsus Pharmaceuticals$66.17+4.1%$62.87$38.51▼$85.25$2.73B0.49594,378 shs1.29 million shs(Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCYTKCytokinetics+0.50%+10.91%+2.90%+31.91%+144.13%KRYSKrystal Biotech-1.33%+5.75%+14.69%+38.99%+159.27%NUVLNuvalent-0.01%+0.06%+20.86%+28.36%+64.56%TARSTarsus Pharmaceuticals+0.63%+2.76%+2.09%+0.65%+56.36%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCYTKCytokinetics 2.86Moderate Buy$99.3024.11% UpsideKRYSKrystal Biotech 2.83Moderate Buy$340.560.10% UpsideNUVLNuvalent 2.20Hold$131.156.25% UpsideTARSTarsus Pharmaceuticals 2.78Moderate Buy$90.6737.02% UpsideCurrent Analyst Ratings BreakdownLatest TARS, NUVL, KRYS, and CYTK Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails6/18/2026KRYSKrystal Biotech TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$306.00 ➝ $403.006/17/2026CYTKCytokinetics Royal Bank Of CanadaSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform$119.006/17/2026CYTKCytokinetics Needham & Company LLCSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingBuy$102.006/16/2026KRYSKrystal Biotech Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingUpgradeBuy (B-) ➝ Buy (B)6/16/2026KRYSKrystal Biotech HC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$310.00 ➝ $361.006/10/2026NUVLNuvalent Sanford C. BernsteinSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform6/10/2026NUVLNuvalent GuggenheimSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$151.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/10/2026NUVLNuvalent UBS GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Neutral$138.00 ➝ $124.006/9/2026NUVLNuvalent Truist FinancialSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$140.00 ➝ $124.006/9/2026NUVLNuvalent TD CowenSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeBuy ➝ Hold$124.00(Data available from 6/23/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCYTKCytokinetics$105.82M94.09N/AN/A($5.39) per share-14.84KRYSKrystal Biotech$389.13M25.77$7.22 per share47.11$42.06 per share8.09NUVLNuvalentN/AN/AN/AN/A$15.95 per shareN/ATARSTarsus Pharmaceuticals$451.36M6.31N/AN/A$8.09 per share8.18Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCYTKCytokinetics-$784.96M-$6.84N/AN/AN/A-784.02%N/A-52.86%8/6/2026 (Estimated)KRYSKrystal Biotech$204.83M$7.4845.4832.37N/A53.92%19.25%17.62%8/3/2026 (Estimated)NUVLNuvalent-$425.38M-$6.06N/AN/AN/AN/A-40.11%-35.43%8/6/2026 (Estimated)TARSTarsus Pharmaceuticals-$66.42M-$1.14N/A22.66N/A-9.02%-14.19%-8.89%8/6/2026 (Estimated)Latest TARS, NUVL, KRYS, and CYTK EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/7/2026Q1 2026NUVLNuvalent-$1.35-$1.39-$0.04-$1.39$0.49 millionN/A5/6/2026Q1 2026TARSTarsus Pharmaceuticals-$0.4003-$0.16+$0.2403-$0.16$149.60 million$162.05 million5/5/2026Q1 2026CYTKCytokinetics-$1.67-$1.67N/A-$1.67$8.52 million$19.36 million5/4/2026Q1 2026KRYSKrystal Biotech$1.45$1.83+$0.38$1.83$112.11 million$116.36 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCYTKCytokineticsN/AN/AN/AN/AN/AKRYSKrystal BiotechN/AN/AN/AN/AN/ANUVLNuvalentN/AN/AN/AN/AN/ATARSTarsus PharmaceuticalsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCYTKCytokineticsN/A4.214.21KRYSKrystal BiotechN/A9.469.06NUVLNuvalentN/A16.1416.14TARSTarsus Pharmaceuticals0.213.743.71Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCYTKCytokineticsN/AKRYSKrystal Biotech86.29%NUVLNuvalent97.26%TARSTarsus Pharmaceuticals90.01%Insider OwnershipCompanyInsider OwnershipCYTKCytokinetics2.60%KRYSKrystal Biotech13.10%NUVLNuvalent5.02%TARSTarsus Pharmaceuticals9.64%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCYTKCytokinetics250124.43 million121.20 millionOptionableKRYSKrystal Biotech21029.48 million25.62 millionOptionableNUVLNuvalent4079.00 million75.03 millionOptionableTARSTarsus Pharmaceuticals5043.02 million38.88 millionOptionableTARS, NUVL, KRYS, and CYTK HeadlinesRecent News About These CompaniesTarsus Pharmaceuticals (NASDAQ:TARS) CEO Bobak Azamian Sells 10,000 SharesJune 23 at 5:03 AM | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) CEO Sells 10,000 Shares of StockJune 23 at 4:21 AM | insidertrades.comTarsus Pharmaceuticals (NASDAQ:TARS) Stock Rating Lowered by Wall Street ZenJune 20 at 1:30 AM | americanbankingnews.comTarsus Pharmaceuticals (NASDAQ:TARS) Downgraded by Wall Street Zen to HoldJune 20 at 1:29 AM | marketbeat.comTarsus: Not Cheap, But Xdemvy Makes The Valuation WorkJune 19, 2026 | seekingalpha.comTarsus Pharmaceuticals (NASDAQ:TARS) Director Sells $183,384.32 in StockJune 18, 2026 | insidertrades.comIshara Investments LP Purchases Shares of 24,000 Tarsus Pharmaceuticals, Inc. $TARSJune 18, 2026 | marketbeat.comCormorant Asset Management LP Lowers Holdings in Tarsus Pharmaceuticals, Inc. $TARSJune 18, 2026 | marketbeat.comTarsus Pharmaceuticals Inc.June 16, 2026 | barrons.comTarsus Pharmaceuticals, Inc. $TARS Shares Sold by Sands Capital Alternatives LLCJune 15, 2026 | marketbeat.comFrazier Life Sciences Management L.P. Sells 438,883 Shares of Tarsus Pharmaceuticals, Inc. $TARSJune 14, 2026 | marketbeat.comA Look At Tarsus Pharmaceuticals (TARS) Valuation After Recent Share Price Strength And Perceived DiscountJune 10, 2026 | finance.yahoo.comClearbridge Investments LLC Cuts Stake in Tarsus Pharmaceuticals, Inc. $TARSJune 10, 2026 | marketbeat.comTarsus Pharmaceuticals (NASDAQ:TARS) Upgraded to Buy at Wall Street ZenJune 6, 2026 | marketbeat.comBNP Paribas Financial Markets Has $29.16 Million Holdings in Tarsus Pharmaceuticals, Inc. $TARSJune 5, 2026 | marketbeat.comTarsus Pharmaceuticals, Inc. (NASDAQ:TARS) Receives Consensus Recommendation of "Moderate Buy" from AnalystsJune 2, 2026 | marketbeat.comTarsus to Participate in Upcoming Investor ConferencesMay 28, 2026 | globenewswire.comLisanti Capital Growth LLC Buys 21,330 Shares of Tarsus Pharmaceuticals, Inc. $TARSMay 24, 2026 | marketbeat.comTarsus taps John Cena for its latest Demodex blepharitis campaignMay 20, 2026 | fiercepharma.comFTarsus Advances TP-05 Lyme Prevention Trial, Setting Up a New Mid-Stage Catalyst for TARS InvestorsMay 20, 2026 | tipranks.comTarsus Pharmaceuticals Inc Ordinary Shares TARSMay 19, 2026 | morningstar.comMNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesSpaceX Gets the Attention, But These 4 Stocks Could Get the ReturnsBy Bridget Bennett | May 25, 20265 Stocks Winning the AI Race While Everyone Watches NVIDIABy Bridget Bennett | May 26, 20265 Under-the-Radar AI Stocks to Watch in JuneBy Thomas Hughes | May 31, 2026Patent Cliff Predators: GSK Acquires Nuvalent For $10.6 BillionBy Jeffrey Neal Johnson | June 11, 20263 Biotech Firms With Major Potential Catalysts in the Coming MonthsBy Nathan Reiff | June 21, 2026TARS, NUVL, KRYS, and CYTK Company DescriptionsCytokinetics NASDAQ:CYTK$80.01 +0.84 (+1.06%) Closing price 04:00 PM EasternExtended Trading$79.90 -0.11 (-0.13%) As of 07:30 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. The company also develops CK-136, a novel cardiac troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase I clinical trial; and aficamten, a novel cardiac myosin inhibitor, which is in Phase III clinical trial for the treatment of patients with symptomatic obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated has a strategic alliance with Ji Xing Pharmaceuticals Limited. The company was incorporated in 1997 and is headquartered in South San Francisco, California.Krystal Biotech NASDAQ:KRYS$340.21 -3.22 (-0.94%) Closing price 04:00 PM EasternExtended Trading$339.82 -0.38 (-0.11%) As of 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, and commercializes genetic medicines for patients with rare diseases in the United States. It commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). The company also develops KB105, which is in Phase 1/2 clinical trials for treating patients with deficient autosomal recessive congenital ichthyosis; KB104 for treating netherton syndrome; KB407 that is in Phase 1 clinical trials for treating cystic fibrosis; KB707 that is in Phase 1 clinical trials for the treatment of anti-PD-1 relapsed/refractory; KB408, which is in Phase 1 clinical trials for treating Alpha-1 antitrypsin deficiency; and KB301 that is in Phase 2 clinical trials for treating aesthetic skin conditions, as well as in open label study with ophthalmic B-VEC for treating for ocular complications of deb. Krystal Biotech, Inc. was founded in 2016 and is headquartered in Pittsburgh, Pennsylvania.Nuvalent NASDAQ:NUVL$123.44 +0.02 (+0.02%) Closing price 04:00 PM EasternExtended Trading$123.03 -0.41 (-0.33%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Nuvalent, Inc., a clinical stage biopharmaceutical company, engages in the development of therapies for patients with cancer. Its lead product candidates are NVL-520, a novel ROS1-selective inhibitor to address the clinical challenges of emergent treatment resistance, central nervous system (CNS)-related adverse events, and brain metastases that may limit the use of ROS1 tyrosine kinase inhibitors (TKIs) for patients with ROS proto-oncogene 1 (ROS1)-positive non-small cell lung cancer (NSCLC) which is under the phase 2 portion of the ARROS-1 Phase 1/2 clinical trial; NVL-655, a brain-penetrant ALK-selective inhibitor, to address the clinical challenges of emergent treatment resistance, CNS-related adverse events, and brain metastases that might limit the use of first-, second-, and third-generation ALK inhibitors that is under the phase 2 portion of the ALKOVE-1 Phase 1/2 clinical trial; and NVL-330, a brain-penetrant human epidermal growth factor receptor 2 (HER2)-selective inhibitor designed to treat tumors driven by HER2ex20, brain metastases, and avoiding treatment-limiting adverse events including due to off-target inhibition of wild-type EGFR, which is expected to initiate phase 1 trial. The company was incorporated in 2017 and is headquartered in Cambridge, Massachusetts.Tarsus Pharmaceuticals NASDAQ:TARS$66.17 +2.61 (+4.11%) As of 04:00 PM EasternTarsus Pharmaceuticals, Inc., a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease. It is developing TP-04 for the treatment of rosacea; and TP-05 for Lyme prophylaxis and community malaria reduction. In addition, the company develops lotilaner to address diseases across therapeutic categories in human medicine, including eye care, dermatology, and other infectious disease prevention. Tarsus Pharmaceuticals, Inc. was incorporated in 2016 and is headquartered in Irvine, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Oracle’s Sell-Off Looks More Like a Mispricing Than a Warning These AI Stocks Have Insider Selling, But Buyers Still Have a Reason to Stay Apple’s Intel Deal Arrives at the Right Time for Its Stock Micron’s Sudden Plunge May Be an AI Buying Chance Amazon’s Pullback Deepens as a New FTC Risk Hits the Stock The Biotech Sector Looks Ready for a Multi-Year Breakout—Here's What to Watch. How Does D-Wave's New Simulator Change the Quantum Computing Landscape? How Intel Is Packaging the Future of American Chips Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
